Will compulsory licensing become the norm? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Will compulsory licensing become the norm?

Mar 14, 2013

It has now been a year since the Indian Patent office granted its first 'compulsory license' for a cancer drug - Nexavar (Sorafenib Tosylate) to Natco Pharma. Naturally the innovator of the drug was discontented by this decision. Let us now take a look at how things have progressed on this front.

Flashback

As per the WTO (World Trade Organization) - "Compulsory licensing is when a government allows someone else to produce the patented product or process without the consent of the patent owner. It is one of the flexibilities on patent protection included in the WTO's agreement on intellectual property - the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement".

The TRIPS Agreement does list a number of conditions for issuing compulsory licenses, in Article 31. In particular:

  • normally the person or company applying for a license has to have tried to negotiate a voluntary license with the patent holder on reasonable commercial terms. Only if that fails can a compulsory license be issued. Thus, in 2010, Natco had filed for voluntary license for Nexavar, however Bayer had refused to grant license filed by Natco) and

  • even when a compulsory license has been issued, the patent owner has to receive payment. In this matter, the TRIPS Agreement says, "the right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorization", but it does not define "adequate remuneration" or "economic value". (As per public sources, Natco will have to pay royalty of 6% to Bayer for sale of Nexavar in India)
Further, as per the TRIPS agreement, compulsory licensing is applicable only when the generic copy is produced mainly for the domestic market, not for export. In 2003, Malaysia was among the initial few countries which had promoted drugs through compulsory licensing. However now, many Asian countries such as Indonesia, Thailand, followed by India in 2012 are taking compulsory licensing route to promote cheaper medicines in their respective markets.

The impact of pricing differentiation

Price difference plays an important role in getting compulsory license. In Natco's case too, the company was able to get the rights of compulsory licensing, as it was able to produce the drug at a significantly lower cost. Indeed, Natco's drug is sold at a 97% discount to the price of the innovator's drug.

But there were other important reasons too - Public requirement or unmet need and manufacturing outside India. As per various public sources, almost 90% of the MNC drugs are imported in India.

Most of the time the drugs which are life threatening in therapies such as cancer, HIV etc are given rights of compulsory licensing.

After Nexavar's approval, Natco is now considering additional launches in the oncology segment and other therapeutic segments. The company is working on approximately 4-5 such drugs, which have the potential to get compulsory license.

Government is now looking to add new cancer drugs in the list

The government has started the process of granting three more compulsory licenses, on cancer treatments from Roche and Bristol-Myers Squibb.

The licensing moves apply to Roche's breast cancer drug Herceptin (Trastuzumab), and Bristol-Myers Squibb's leukemia treatment Sprycel (dasatinib) and breast cancer therapy Ixempra (Ixabepilone). It would be the first round of new compulsory licenses since India issued its first in March, on Bayer's kidney cancer treatment Nexavar.

Stance of the Innovator companies

In Nexavar's case, Bayer had filed various litigation suits against the Indian patent office as well as Natco. Various reasons were given by Bayer to protect its brand. But nothing has been working so far.

Recently, the Indian Intellectual Property Appellate Board (IPAB) upheld a decision to allow Natco Pharma to sell a generic version of Bayer's cancer drug Nexavar. However, the royalty payment to Bayer was increased from 6% to 7%.

Our View

Competition is already intensifying in the domestic pharma market and there would be further challenges in store in the event that the new drug Pricing Policy comes into force. Thus, there could be some headwinds for the domestic pharma market going forward. In such a scenario, compulsory licensing will act as a low competition opportunity for a period of time. Besides Nexavar, Natco has already begun work on more such opportunities, and in that sense is ahead of the curve than other Indian companies. However as the government is in the process of bringing more drugs under compulsory licensing, the possibility of competition entering this space too cannot be ruled out.

But there is the other side of the coin too. Though compulsory licensing looks attractive, there are barriers which could be raised by the innovator of the drugs, which should also be considered by investors. Thus, even after a company gets compulsory license, the innovator could take various steps to protect its patent and reduce the value for the generic company. Thus investors should be aware about such actions. Ultimately, the opportunity from compulsory license would depend upon the nature and size of the drug and the patents surrounding the same and should be evaluated accordingly.


Equitymaster requests your view! Post a comment on "Will compulsory licensing become the norm?". Click here!

  

More Views on News

LAURUS LABS LTD Share Price Up by 5%; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Sep 28, 2020 | Updated on Sep 28, 2020

LAURUS LABS LTD share price is trading up by 5% and its current market price is Rs 1,394. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index is LAURUS LABS LTD (up 5.0%). The top losers are NARAYANA HRUDAYALAYA LTD and GSK PHARMA (down 0.1%).

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 28, 2020 09:49 AM

MARKET STATS